Tamoxifen is a selective estrogen receptor-α (ERα) modulator that competitively inhibits the estrogen–receptor interaction, and this provides its usage in the treatment of women with ER-positive (ER+) BC [104]. The gene discussed is ESR1; the disease is breast cancer.